5:24 PM
 | 
Aug 02, 2018
 |  BioCentury  |  Finance

Appetite for Omniome

How next-gen sequencing play Omniome raised its B round led by Chinese investors

An experienced team and a growing DNA sequencing market in China enabled San Diego’s Omniome Inc. to raise a $60 million series B round led by Chinese investors.

Decheng Capital and Hillhouse Capital Group co-led the round, which closed July 30. Fellow new investors Lam Research Capital and Nan Fung Life Sciences also participated, as did existing investors Arch Venture Partners, Domain Associates, Biomatics Capital Partners and Altitude Life Science Ventures.

“Investors have witnessed...

Read the full 355 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >